Do analysts prefer TXMD or BMEA?

Biomea Fusion has a consensus price target of $8.50, indicating a potential upside of 580.00%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts plainly believe Biomea Fusion is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biomea Fusion 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75

Do analysts prefer TXMD or KLRS?

Kalaris Therapeutics has a consensus price target of $18.75, indicating a potential upside of 402.68%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kalaris Therapeutics is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kalaris Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88

Do analysts rate TXMD or VRCA?

Verrica Pharmaceuticals has a consensus price target of $14.50, suggesting a potential upside of 188.84%. Given Verrica Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Verrica Pharmaceuticals is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Verrica Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts rate TXMD or AADI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate TXMD or BTMD?

biote has a consensus price target of $2.75, suggesting a potential upside of 20.61%. Given biote's stronger consensus rating and higher probable upside, analysts plainly believe biote is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 biote 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has better earnings and valuation, TXMD or BTMD?

biote has higher revenue and earnings than TherapeuticsMD. biote is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TherapeuticsMD $3.02M 7.89 -$570K $0.06 34.33 biote $192.22M 0.45 $27.05M $0.44 5.18

Is TXMD or BTMD more profitable?

biote has a net margin of 8.29% compared to TherapeuticsMD's net margin of 5.34%. TherapeuticsMD's return on equity of 0.32% beat biote's return on equity. Company Net Margins Return on Equity Return on Assets TherapeuticsMD 5.34% 0.32% 0.23% biote 8.29% -25.72% 15.12%

TherapeuticsMD (TXMD) Competitors

$2.06 0.00 (0.00%)

As of 07/24/2026 04:00 PM Eastern

Compare

TXMD vs. BMEA, KLRS, VRCA, AADI, and BTMD

Should you buy TherapeuticsMD stock or one of its competitors? MarketBeat compares TherapeuticsMD with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TherapeuticsMD include Biomea Fusion (BMEA), Kalaris Therapeutics (KLRS), Verrica Pharmaceuticals (VRCA), Aadi Bioscience (AADI), and biote (BTMD). These companies are all part of the "pharmaceutical products" industry.

How does TherapeuticsMD compare to Biomea Fusion?

TherapeuticsMD (NASDAQ:TXMD) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 1.7% of TherapeuticsMD shares are held by insiders. Comparatively, 10.6% of Biomea Fusion shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Biomea Fusion has a consensus price target of $8.50, indicating a potential upside of 580.00%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts plainly believe Biomea Fusion is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

TherapeuticsMD has a net margin of 5.34% compared to Biomea Fusion's net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
Biomea Fusion	N/A	-265.37%	-103.96%

In the previous week, TherapeuticsMD and TherapeuticsMD both had 1 articles in the media. Biomea Fusion's average media sentiment score of 1.89 beat TherapeuticsMD's score of 1.87 indicating that Biomea Fusion is being referred to more favorably in the news media.

Company	Overall Sentiment
TherapeuticsMD	Very Positive
Biomea Fusion	Very Positive

TherapeuticsMD has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.31, indicating that its share price is 131% less volatile than the broader market.

TherapeuticsMD has higher revenue and earnings than Biomea Fusion. Biomea Fusion is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	7.89	-$570K	$0.06	34.33
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A

Summary

TherapeuticsMD beats Biomea Fusion on 8 of the 14 factors compared between the two stocks.

How does TherapeuticsMD compare to Kalaris Therapeutics?

TherapeuticsMD (NASDAQ:TXMD) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

TherapeuticsMD has a net margin of 5.34% compared to Kalaris Therapeutics' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
Kalaris Therapeutics	N/A	-72.78%	-43.49%

In the previous week, Kalaris Therapeutics had 2 more articles in the media than TherapeuticsMD. MarketBeat recorded 3 mentions for Kalaris Therapeutics and 1 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 1.87 beat Kalaris Therapeutics' score of 0.62 indicating that TherapeuticsMD is being referred to more favorably in the media.

Company	Overall Sentiment
TherapeuticsMD	Very Positive
Kalaris Therapeutics	Positive

TherapeuticsMD has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market.

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

TherapeuticsMD has higher revenue and earnings than Kalaris Therapeutics. Kalaris Therapeutics is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	7.89	-$570K	$0.06	34.33
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A

Kalaris Therapeutics has a consensus price target of $18.75, indicating a potential upside of 402.68%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kalaris Therapeutics is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

TherapeuticsMD beats Kalaris Therapeutics on 9 of the 16 factors compared between the two stocks.

How does TherapeuticsMD compare to Verrica Pharmaceuticals?

TherapeuticsMD (NASDAQ:TXMD) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

In the previous week, Verrica Pharmaceuticals had 5 more articles in the media than TherapeuticsMD. MarketBeat recorded 6 mentions for Verrica Pharmaceuticals and 1 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 1.87 beat Verrica Pharmaceuticals' score of 0.49 indicating that TherapeuticsMD is being referred to more favorably in the media.

Company	Overall Sentiment
TherapeuticsMD	Very Positive
Verrica Pharmaceuticals	Neutral

TherapeuticsMD has a net margin of 5.34% compared to Verrica Pharmaceuticals' net margin of -47.97%. TherapeuticsMD's return on equity of 0.32% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%

30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 1.7% of TherapeuticsMD shares are held by insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Verrica Pharmaceuticals has a consensus price target of $14.50, suggesting a potential upside of 188.84%. Given Verrica Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Verrica Pharmaceuticals is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

TherapeuticsMD has higher earnings, but lower revenue than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	7.89	-$570K	$0.06	34.33
Verrica Pharmaceuticals	$35.58M	2.42	-$17.89M	-$1.03	N/A

TherapeuticsMD has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market.

Summary

TherapeuticsMD and Verrica Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does TherapeuticsMD compare to Aadi Bioscience?

TherapeuticsMD (NASDAQ:TXMD) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, TherapeuticsMD and TherapeuticsMD both had 1 articles in the media. TherapeuticsMD's average media sentiment score of 1.87 beat Aadi Bioscience's score of -0.71 indicating that TherapeuticsMD is being referred to more favorably in the media.

Company	Overall Sentiment
TherapeuticsMD	Very Positive
Aadi Bioscience	Negative

TherapeuticsMD has a net margin of 5.34% compared to Aadi Bioscience's net margin of -246.06%. TherapeuticsMD's return on equity of 0.32% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

TherapeuticsMD has higher earnings, but lower revenue than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	7.89	-$570K	$0.06	34.33
Aadi Bioscience	$25.07M	3.65	-$65.76M	-$2.35	N/A

30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are held by institutional investors. 1.7% of TherapeuticsMD shares are held by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

TherapeuticsMD has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

Summary

TherapeuticsMD beats Aadi Bioscience on 9 of the 13 factors compared between the two stocks.

How does TherapeuticsMD compare to biote?

TherapeuticsMD (NASDAQ:TXMD) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

biote has higher revenue and earnings than TherapeuticsMD. biote is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	7.89	-$570K	$0.06	34.33
biote	$192.22M	0.45	$27.05M	$0.44	5.18

biote has a consensus price target of $2.75, suggesting a potential upside of 20.61%. Given biote's stronger consensus rating and higher probable upside, analysts plainly believe biote is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 1.7% of TherapeuticsMD shares are held by insiders. Comparatively, 32.4% of biote shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, biote had 1 more articles in the media than TherapeuticsMD. MarketBeat recorded 2 mentions for biote and 1 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 1.87 beat biote's score of 0.94 indicating that TherapeuticsMD is being referred to more favorably in the media.

Company	Overall Sentiment
TherapeuticsMD	Very Positive
biote	Positive

biote has a net margin of 8.29% compared to TherapeuticsMD's net margin of 5.34%. TherapeuticsMD's return on equity of 0.32% beat biote's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
biote	8.29%	-25.72%	15.12%

TherapeuticsMD has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market. Comparatively, biote has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market.

Summary

biote beats TherapeuticsMD on 12 of the 17 factors compared between the two stocks.

Get TherapeuticsMD News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TXMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TXMD vs. The Competition

Export

Metric	TherapeuticsMD	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$23.84M	$3.08B	$7.07B	$12.22B
Dividend Yield	N/A	2.07%	2.67%	9.42%
P/E Ratio	34.33	20.29	27.14	23.62
Price / Sales	7.89	339.70	523.79	89.78
Price / Cash	44.15	26.63	26.39	46.67
Price / Book	0.89	4.13	10.30	6.08
Net Income	-$570K	$65.94M	$3.60B	$331.70M
7 Day Performance	N/A	-4.16%	-1.27%	-0.63%
1 Month Performance	-2.37%	-5.47%	-1.67%	-3.04%
1 Year Performance	73.11%	9.95%	18.25%	13.30%

TherapeuticsMD Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TXMD TherapeuticsMD	1.7235 of 5 stars	$2.06 flat	N/A	+73.1%	$23.84M	$3.02M	34.33	420	Positive News
BMEA Biomea Fusion	3.4874 of 5 stars	$1.33 +1.5%	$8.50 +539.1%	-31.7%	$96.16M	N/A	N/A	50	Positive News
KLRS Kalaris Therapeutics	3.8852 of 5 stars	$4.04 +1.0%	$15.60 +286.1%	+35.1%	$95.17M	N/A	N/A	110
VRCA Verrica Pharmaceuticals	2.4758 of 5 stars	$5.44 -0.9%	$14.50 +166.5%	-24.1%	$94.31M	$37.16M	N/A	40	News Coverage Analyst Downgrade
AADI Aadi Bioscience	N/A	$3.79 -2.6%	N/A	+91.2%	$93.60M	$25.07M	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TXMD) was last updated on 7/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TherapeuticsMD (TXMD) Competitors

TXMD vs. BMEA, KLRS, VRCA, AADI, and BTMD

How does TherapeuticsMD compare to Biomea Fusion?

Summary

How does TherapeuticsMD compare to Kalaris Therapeutics?

Summary

How does TherapeuticsMD compare to Verrica Pharmaceuticals?

Summary

How does TherapeuticsMD compare to Aadi Bioscience?

Summary

How does TherapeuticsMD compare to biote?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXMD vs. The Competition

TherapeuticsMD Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TherapeuticsMD (TXMD) Competitors

TXMD vs. BMEA, KLRS, VRCA, AADI, and BTMD

How does TherapeuticsMD compare to Biomea Fusion?

Do institutionals & insiders believe in TXMD or BMEA?

Do analysts prefer TXMD or BMEA?

Is TXMD or BMEA more profitable?

Does the media favor TXMD or BMEA?

Which has more volatility & risk, TXMD or BMEA?

Which has better earnings and valuation, TXMD or BMEA?

Summary

How does TherapeuticsMD compare to Kalaris Therapeutics?

Is TXMD or KLRS more profitable?

Does the media prefer TXMD or KLRS?

Which has more risk & volatility, TXMD or KLRS?

Do institutionals & insiders believe in TXMD or KLRS?

Which has better earnings & valuation, TXMD or KLRS?

Do analysts prefer TXMD or KLRS?

Summary

How does TherapeuticsMD compare to Verrica Pharmaceuticals?

Does the media prefer TXMD or VRCA?

Is TXMD or VRCA more profitable?

Do institutionals and insiders have more ownership in TXMD or VRCA?

Do analysts rate TXMD or VRCA?

Which has preferable valuation and earnings, TXMD or VRCA?

Which has more risk and volatility, TXMD or VRCA?

Summary

How does TherapeuticsMD compare to Aadi Bioscience?

Do analysts rate TXMD or AADI?

Does the media favor TXMD or AADI?

Is TXMD or AADI more profitable?

Which has stronger earnings & valuation, TXMD or AADI?

Do insiders and institutionals have more ownership in TXMD or AADI?

Which has more volatility and risk, TXMD or AADI?

Summary

How does TherapeuticsMD compare to biote?

Which has better earnings and valuation, TXMD or BTMD?

Do analysts rate TXMD or BTMD?

Do insiders & institutionals have more ownership in TXMD or BTMD?

Does the media favor TXMD or BTMD?

Is TXMD or BTMD more profitable?

Which has more risk & volatility, TXMD or BTMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXMD vs. The Competition

TherapeuticsMD Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools